A new drug combo using trastuzumab deruxtecan (T-DXd) nearly halved disease progression in HER2-positive metastatic breast cancer. Called a “smart bomb,” it targets cancer cells directly. Patients saw significantly improved outcomes over standard care. The treatment could soon become a first-line option pending regulatory approval, experts say.
We'll keep you updated on all new application updates and features!